Who makes dicrofenac and travoprost?

dicrofenac and travoprost is developed by Tokyo University.

What development phase is dicrofenac and travoprost in?

dicrofenac and travoprost is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

dicrofenac and travoprost

Tokyo University · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	dicrofenac and travoprost
Sponsor	Tokyo University
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effect of NSAID on Travoprost-induced Conjunctival Hyperemia and IOP Reduction in Normal Eyes (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

dicrofenac and travoprost CI brief — competitive landscape report
dicrofenac and travoprost updates RSS · CI watch RSS
Tokyo University portfolio CI